Invesco
RCUS icon

Invesco’s Arcus Biosciences RCUS Stock Holding History

Invesco’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1M Buy
845,233
+24,413
+3% +$603K ﹤0.01% 1384
2026
Q1 		$17.7M Buy
820,820
+406,455
+98% +$8.78M ﹤0.01% 1513
2025
Q4 		$9.87M Buy
414,365
+121,961
+42% +$2.49M ﹤0.01% 1849
2025
Q3 		$3.98M Buy
292,404
+40,553
+16% +$422K ﹤0.01% 2337
2025
Q2 		$2.05M Sell
251,851
-2,173
-0.9% -$18.6K ﹤0.01% 2572
2025
Q1 		$1.99M Buy
254,024
+50,037
+25% +$580K ﹤0.01% 2553
2024
Q4 		$3.04M Buy
203,987
+35,905
+21% +$586K ﹤0.01% 2461
2024
Q3 		$2.57M Sell
168,082
-14,358
-8% -$226K ﹤0.01% 2509
2024
Q2 		$2.78M Sell
182,440
-8,243
-4% -$133K ﹤0.01% 2459
2024
Q1 		$3.6M Sell
190,683
-1,947
-1% -$33.7K ﹤0.01% 2415
2023
Q4 		$3.68M Sell
192,630
-40,174
-17% -$642K ﹤0.01% 2392
2023
Q3 		$4.18M Sell
232,804
-16,361
-7% -$329K ﹤0.01% 2298
2023
Q2 		$5.06M Sell
249,165
-33,954
-12% -$647K ﹤0.01% 2233
2023
Q1 		$5.16M Buy
283,119
+10,841
+4% +$207K ﹤0.01% 2200
2022
Q4 		$5.63M Buy
272,278
+5,764
+2% +$159K ﹤0.01% 2184
2022
Q3 		$6.97M Sell
266,514
-74,250
-22% -$1.96M ﹤0.01% 2021
2022
Q2 		$8.63M Buy
340,764
+47,290
+16% +$1.16M ﹤0.01% 1950
2022
Q1 		$9.26M Buy
293,474
+94,844
+48% +$3.18M ﹤0.01% 2000
2021
Q4 		$8.04M Sell
198,630
-26,054
-12% -$1.01M ﹤0.01% 2140
2021
Q3 		$7.83M Buy
224,684
+6,331
+3% +$197K ﹤0.01% 2142
2021
Q2 		$6M Sell
218,353
-79,524
-27% -$2.27M ﹤0.01% 2352
2021
Q1 		$8.36M Sell
297,877
-6,881
-2% -$239K ﹤0.01% 2066
2020
Q4 		$7.91M Buy
304,758
+18,492
+6% +$448K ﹤0.01% 1929
2020
Q3 		$4.91M Sell
286,266
-5,180
-2% -$116K ﹤0.01% 2017
2020
Q2 		$7.21M Buy
291,446
+5,155
+2% +$139K ﹤0.01% 1809
2020
Q1 		$3.97M Buy
+286,291
New +$3.56M ﹤0.01% 2012

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Invesco's RCUS Position: Q2 2026 in Review

Invesco increased its Arcus Biosciences (RCUS) stake by 3% in Q2 2026, buying an estimated $603K and bringing the position to 845,233 shares worth $26.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1384.

Invesco first reported a position in RCUS in Q1 2020 and has held it in 26 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Invesco held 845,233 shares of Arcus Biosciences worth $26.1M as of Q2 2026.
  • Invesco bought 24,413 Arcus Biosciences shares in Q2 2026, an estimated $603K.
  • Arcus Biosciences made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1384 holding.
  • Invesco first reported a position in Arcus Biosciences in Q1 2020 and has held it in 26 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.